Chronic Pain Syndrome: When Pain Becomes a Disease

Chronic pain syndrome (CPS) is pain lasting longer than three months that has become a condition in its own right, with depression, anxiety, poor sleep and disability feeding the pain through central sensitization. The International Association for the Study of Pain (IASP) and the World Health Organization recognized a closely related diagnosis in ICD-11 in 2019, “chronic primary pain” [1]. US clinicians code chronic pain syndrome as ICD-10-CM G89.4.

What Chronic Pain Syndrome Actually Is

There’s a critical difference between having chronic pain and having chronic pain syndrome. Both involve pain that persists beyond the expected healing time, typically defined as longer than three months. But chronic pain syndrome is a more complex, more disabling condition in which pain is accompanied by significant changes in mood, sleep, cognition, and daily function, and where these changes have become interlocked in a cycle that perpetuates itself.

The ICD-11 added “chronic primary pain” as a standalone diagnosis in 2019, recognizing what pain researchers had known for years: in some patients, pain becomes the disease itself rather than a symptom of something else [1]. This isn’t semantic wordplay. It has real treatment implications. If you’re treating only the joint, or only the back, or only the nerve, you’re missing most of the problem.

The condition goes by several names. Clinicians and researchers use chronic primary pain (the ICD-11 term), nociplastic pain (the IASP mechanism term adopted in 2017 for pain driven by altered pain processing rather than tissue or nerve damage), centralized pain, and central sensitivity syndromes, the umbrella term the rheumatologist Muhammad Yunus used for fibromyalgia and its overlapping conditions. The chronic pain condition page covers pain of every type.

How common is chronic pain syndrome?

According to the CDC’s National Health Interview Survey analysis (Rickard et al., 2023), 20.9% of US adults had chronic pain in 2021 and 6.9% had high-impact chronic pain, meaning pain that substantially restricts work, social life or self care. No national survey counts CPS separately; high-impact chronic pain is the closest measure.

Chronic Pain vs Chronic Pain Syndrome: Key Differences

Chronic pain is a duration: pain lasting more than three months. Chronic pain syndrome is a pattern: long-lasting pain plus the mood, sleep, cognitive and functional changes that keep it going.

How Pain Becomes a Syndrome

The Neuroscience of Central Sensitization

When pain signals persistently bombard the spinal cord and brain, the system does not passively receive them. It adapts, and often not in a helpful way. Neurons in the dorsal horn of the spinal cord become more excitable, responding to lighter stimuli and firing more readily. This is called peripheral sensitization. When the changes extend into the central nervous system, it becomes central sensitization [2].

In someone with central sensitization, several things happen. Normal touch can become painful (allodynia). Painful stimuli cause more pain than they should (hyperalgesia). Pain spreads beyond the original injury site. And areas of the brain involved in pain processing, the anterior cingulate cortex, the insula, the prefrontal cortex, show structural and functional changes visible on neuroimaging [3].

The descending pain modulation system, which normally acts as a brake on incoming pain signals, also weakens. The brainstem structures that release endogenous opioids, serotonin, and norepinephrine to suppress pain signals become less effective. Pain begets more pain through mechanisms that have nothing to do with ongoing tissue damage.

The Role of Neuroinflammation

Research over the past decade has identified neuroinflammation as a key driver of chronic pain syndrome. Activated microglia, the brain’s immune cells, release pro-inflammatory cytokines that sensitize pain pathways and contribute to the mood and cognitive symptoms that often accompany CPS [4]. This explains, at least partly, why conditions like fibromyalgia and CRPS involve widespread symptoms that go far beyond any single injury site.

Elevated levels of inflammatory markers including TNF-alpha, IL-6, and IL-1beta have been found in cerebrospinal fluid and blood in patients with fibromyalgia and other chronic pain conditions. This is a biological finding, not a psychological one.

The Psychological-Biological Feedback Loop

Chronic pain reliably produces depression, anxiety, and sleep disturbance. This isn’t weakness or an overreaction. The same brain circuits that process pain overlap significantly with those that regulate mood and stress responses. Persistent activation of pain circuits alters the HPA axis stress response, depletes dopamine in reward circuits, and disrupts sleep architecture, all of which, in turn, lower the threshold for pain perception [5].

This is why chronic pain syndrome is so much harder to treat than simple chronic pain. The depression isn’t just a reaction to pain; it actively amplifies it. The sleep disruption isn’t just unpleasant; it increases central sensitization. Each component worsens the others.

The mechanisms behind each pain type, nociceptive, neuropathic and nociplastic, are laid out in more detail in our post on chronic pain types and mechanisms.

Symptoms of Chronic Pain Syndrome

The core symptom of chronic pain syndrome is pain lasting longer than three months that is out of proportion to any remaining tissue damage and comes with changes in mood, sleep and function. It is the combination of signs below, rather than any one symptom, that points to the syndrome.

• Pain that spreads beyond the original injury or shifts between body regions.
• Allodynia, where light touch, clothing or a hug hurts, and hyperalgesia, where a mildly painful stimulus hurts far more than expected.
• Unrefreshing sleep, insomnia or frequent waking, which then makes the next day’s pain worse.
• Fatigue, brain fog, depression, anxiety or a sense of helplessness about the pain.
• Withdrawal from work, exercise and social life because of pain or fear of a flare.

New or rapidly worsening pain, or pain with fever, weight loss, weakness or loss of bladder control, needs prompt assessment for another cause.

Who Develops Chronic Pain Syndrome

Not everyone with an injury or painful condition develops CPS. Several factors increase the risk.

Biological Factors

Genetic variations affecting serotonin and dopamine neurotransmission, as well as variants in genes regulating COMT (catechol-O-methyltransferase), influence how sensitized the nervous system becomes in response to pain [6]. People with a family history of chronic pain conditions are at higher risk, as are those with pre-existing sleep disorders.

Psychological Factors

Pain catastrophizing, the tendency to ruminate on pain, magnify its threat, and feel helpless, is one of the strongest predictors of who develops chronic pain syndrome following an injury. This is not a personality flaw. Pain catastrophizing reflects nervous system hypervigilance that can be specifically targeted and reduced with appropriate therapy. A history of trauma or adverse childhood experiences also significantly increases CPS risk, likely through long-term effects on HPA axis regulation and stress reactivity [7].

Social and Contextual Factors

Being involved in litigation over an injury, job dissatisfaction, and social isolation all increase the likelihood that acute pain transitions to CPS. These are not reasons to dismiss the pain. They are modifiable factors that a comprehensive treatment plan should address.

Diagnosing Chronic Pain Syndrome

There’s no blood test for CPS, which leads to underdiagnosis and, sometimes, dismissal. Clinicians who understand the condition use a combination of clinical history, validated questionnaires, and sometimes quantitative sensory testing (QST) to assess the degree of central sensitization present.

The Central Sensitization Inventory (CSI) is a validated 25-item questionnaire that can help identify central sensitization and differentiate CPS from purely peripheral pain conditions [8]. Pressure pain threshold testing, where a calibrated device measures the pressure at which stimulation becomes painful, can quantify hyperalgesia and track it over time.

Functional MRI has demonstrated characteristic patterns of altered connectivity in pain networks in fibromyalgia and other CPS conditions, though this remains primarily a research tool rather than a clinical diagnostic test.

What is the ICD code for chronic pain syndrome?

The ICD-10-CM code for chronic pain syndrome is G89.4, which US clinicians and insurers use for billing and records. Under ICD-11, the WHO system that took effect internationally in 2022, the matching diagnosis is chronic primary pain, with subtypes such as chronic widespread pain and complex regional pain syndrome. Our post on the G89.4 code explains when it is used.

Conditions that overlap with chronic pain syndrome

Central sensitization sits behind a group of conditions that often occur together and that many clinicians treat as part of the same spectrum. These include fibromyalgia, complex regional pain syndrome (CRPS), chronic low back pain without a clear structural cause, irritable bowel syndrome, temporomandibular joint disorder, chronic migraine and tension-type headache, and chronic fatigue syndrome. Having one raises the odds of another.

Treatment Approaches Specific to Chronic Pain Syndrome

Chronic pain syndrome treatment works best when it targets the sensitized nervous system, mood and sleep together, rather than the original injury alone. Most plans combine medication, active rehabilitation, psychological therapy and, for some patients, neuromodulation. The chronic pain treatment guide covers the full range of options beyond CPS.

Targeting Central Sensitization Directly

Duloxetine and milnacipran (SNRIs) work in part by enhancing descending pain inhibition through serotonin and norepinephrine. Pregabalin and gabapentin reduce neuronal excitability by binding to calcium channels on hyperexcitable neurons. Low-dose naltrexone (LDN) at doses around 1 to 4.5mg has shown anti-neuroinflammatory effects through its action on microglial toll-like receptors, with promising early evidence for fibromyalgia and other central sensitization conditions [9].

The regulatory picture differs by drug. The FDA has approved duloxetine, milnacipran and pregabalin for fibromyalgia, and duloxetine and pregabalin carry approvals for some neuropathic pain conditions as well. LDN is off label for every pain use: naltrexone is approved at 50 mg for opioid and alcohol use disorder, so the low doses used for pain are usually compounded and paid out of pocket. The supporting trials, including a small crossover study by Jarred Younger and colleagues (2013), are encouraging but small.

Ketamine Infusions

Ketamine’s NMDA receptor antagonism directly interrupts the long-term potentiation in spinal cord neurons that underlies central sensitization. A series of ketamine infusions can essentially “reset” sensitized pain circuits in some patients, providing relief that extends weeks to months beyond the infusions themselves [10]. This is one of the more mechanism-targeted treatments available for CPS, and it’s most appropriate for patients with clear central sensitization components, including those with complex regional pain syndrome, fibromyalgia, or chronic pain following surgery.

Ketamine is FDA approved as an anesthetic, so infusions for chronic pain are off label, and insurers often decline to cover them. The 2019 meta-analysis by Orhurhu and colleagues found short-term pain reduction across randomized trials, with less certainty about how long benefits last [10]. Infusions are given by anesthesiologists or pain physicians with heart rate, blood pressure and oxygen monitoring; the ketamine therapy treatment guide describes what a session involves, and you can compare clinics offering ketamine infusions by location.

Transcranial Magnetic Stimulation and Neurofeedback

Repetitive TMS applied to the motor cortex or dorsolateral prefrontal cortex modulates activity in pain-processing and pain-modulation networks. Multiple sham-controlled trials have found significant reductions in chronic pain with rTMS, including for fibromyalgia and neuropathic pain [11]. The effects appear to outlast the stimulation period, suggesting lasting neuroplastic changes.

The European guideline by Jean-Pascal Lefaucheur and colleagues (2020) rated high-frequency rTMS of the motor cortex as having definite efficacy for neuropathic pain [11]. In the US, the FDA has cleared TMS devices for depression, obsessive-compulsive disorder, smoking cessation and migraine, but not for chronic pain, so rTMS for CPS is off label and usually self-pay. The TMS treatment guide explains the protocols, and the national TMS clinic list shows who offers it.

Neurofeedback takes a different approach, training patients to voluntarily alter their own EEG patterns using real-time feedback. Protocols targeting theta and alpha brainwave activity have shown reductions in pain intensity and improvements in sleep quality in small trials for fibromyalgia and chronic regional pain [12]. The mechanism involves strengthening inhibitory circuits and normalizing the hyperaroused pain networks characteristic of CPS.

Evidence for neurofeedback in pain is thinner than for rTMS. Related approaches such as heart rate variability biofeedback are covered in our post on biofeedback for chronic pain.

Psychological Treatments

Pain neuroscience education (PNE) is an intervention that specifically teaches patients about central sensitization and the biology underlying their experience. A systematic review found that PNE reduces pain catastrophizing, improves physical functioning, and decreases pain intensity, with effects that persist at follow-up [13]. The mechanism is partly cognitive (changing unhelpful beliefs that amplify pain) and partly neurobiological (reducing the threat value of pain signals, which directly affects how the nervous system processes them).

Acceptance and Commitment Therapy (ACT) for chronic pain focuses on reducing avoidance of pain-related activities and building psychological flexibility. Unlike traditional CBT, ACT doesn’t aim primarily to reduce pain but to reduce the suffering and disability associated with it. Randomized trials have shown meaningful improvements in function and quality of life, and these gains hold up at long-term follow-up.

Cognitive behavioral therapy for chronic pain (CBT-CP) and CBT for insomnia (CBT-I) round out the main psychological options. Pain psychologists deliver them, often with insurance coverage.

Opioids and chronic pain syndrome

Long-term opioids are a poor fit for most people with chronic pain syndrome, because they do little for central sensitization and can worsen pain sensitivity over time through opioid-induced hyperalgesia. The CDC Clinical Practice Guideline for Prescribing Opioids for Pain (Dowell et al., 2022) states that nonopioid therapies are preferred for chronic pain and that any opioid trial should be weighed carefully against its risks. Anyone taking opioids should taper only with their prescriber. Our post on chronic pain management without opioids covers the alternatives.

Interdisciplinary pain rehabilitation

Interdisciplinary pain rehabilitation programs bring a pain physician, physical therapist, occupational therapist and pain psychologist together on one coordinated plan, usually over several weeks. These programs target function, activity and mood rather than pain scores alone, which matches how CPS behaves. Availability varies by region, so ask a pain medicine physician whether one is within reach.

Regenerative Approaches in Chronic Pain Syndrome

Where CPS involves an identifiable structural driver, such as joint degeneration, ligament laxity, or nerve entrapment, regenerative therapies can address the peripheral pain generator that feeds the central sensitization. Removing or reducing the peripheral input doesn’t automatically reverse central sensitization, but it can significantly reduce the burden on sensitized pain circuits and make other treatments more effective.

Platelet-rich plasma for knee osteoarthritis, prolotherapy for ligamentous laxity, and shockwave therapy for chronic tendinopathies have all shown efficacy in reducing pain from the peripheral sources that may have initiated the sensitization process. In practice, combining these peripheral treatments with centrally-targeted approaches like ketamine or TMS gives many CPS patients their best chance of meaningful improvement.

BPC-157 has demonstrated the ability to reduce neuroinflammation and promote healing in neural tissue in preclinical studies, suggesting a potential role in addressing both the peripheral and central components of chronic pain syndrome, though clinical trials are needed to confirm these effects in humans.

These regenerative options are mostly cash pay. PRP injections for joint pain are not FDA approved for that use and are rarely covered, and BPC-157 is not approved by the FDA for any human use. The PRP treatment guide sets out what the evidence does and does not show for joint and tendon pain.

How the main chronic pain syndrome treatments compare

Each approach targets a different part of the syndrome, and the evidence and US regulatory status vary widely.

Who Treats Chronic Pain Syndrome

Chronic pain syndrome is usually treated by a pain medicine physician, often with training in anesthesiology or physical medicine and rehabilitation (PM&R), working alongside a pain psychologist and a physical therapist. Rheumatologists commonly manage fibromyalgia, neurologists manage neuropathic pain and migraine, and primary care physicians coordinate long-term care.

A good first visit covers pain history, sleep, mood, function and medications, not just imaging. Useful guides for conditions under CPS include fibromyalgia treatment options, CRPS treatment and chronic low back pain treatment.

Finding a chronic pain syndrome clinic

Regenerated.com lists clinics offering treatments used for chronic pain, such as ketamine infusions, rTMS and PRP, by city and state. Listing order is not paid ranking, Featured slots are clearly labeled and capped, Verified means the clinic completed the credential checks described in our vetting materials, and the directory is free for patients. Inclusion is not an endorsement, so ask each clinic who supervises treatment, how they assess central sensitization, and which parts are off label. Our guide to Featured, Verified and organic listings explains how to read a clinic list.

Living With and Recovering From Chronic Pain Syndrome

Recovery from CPS is real and it happens. It typically isn’t fast, and it rarely looks like returning to zero pain. More often it looks like steadily rebuilding function, reducing pain’s interference with life, and gradually reversing the central sensitization that has accumulated over months or years. Pacing, graded activity, and sleep optimization are foundational. Sleep deprivation is one of the most potent amplifiers of central sensitization, and addressing it aggressively, whether through medication, CBT for insomnia, or sleep hygiene changes, pays dividends across all other treatments.

The trajectory of CPS is not fixed. The same neuroplasticity that allowed the nervous system to sensitize itself is also what allows it to normalize, given the right inputs over enough time.

Daily habits that support recovery

1. Pace activity from a baseline you can manage on a bad day, building up in small planned steps.
2. Protect sleep with a fixed wake time, and ask about CBT-I if insomnia persists.
3. Do low-impact exercise most days, such as walking, swimming or cycling.
4. Track function, such as minutes walked, alongside pain scores, since function often improves first.

Frequently asked questions

Is chronic pain syndrome a real diagnosis?

Yes. Chronic pain syndrome is a recognized diagnosis with its own ICD-10-CM code, G89.4, and ICD-11 added the related diagnosis chronic primary pain in 2019 after work led by the International Association for the Study of Pain. It describes pain lasting more than three months that comes with lasting changes in mood, sleep and function, driven by measurable central sensitization rather than imagination or weakness.

What is the ICD-10 code for chronic pain syndrome?

The ICD-10-CM code for chronic pain syndrome is G89.4. It is used when chronic pain comes with significant psychological and functional effects, and it is separate from the G89.2x codes for chronic pain not elsewhere classified. Under ICD-11, the closest diagnosis is chronic primary pain. Clinicians often record G89.4 alongside codes for underlying conditions such as fibromyalgia or low back pain.

Can chronic pain syndrome go away?

Chronic pain syndrome can improve substantially, and many people regain function and reduce how much pain controls their life. Recovery is usually gradual and rarely means zero pain. The neuroplasticity that sensitized the nervous system also lets it settle, especially with a combined plan of graded activity, better sleep, psychological therapy such as pain neuroscience education or ACT, and medication or neuromodulation where they fit.

What kind of doctor treats chronic pain syndrome?

A pain medicine physician, often trained in anesthesiology or physical medicine and rehabilitation, usually leads care for chronic pain syndrome. Most effective plans add a pain psychologist and a physical therapist, and many people also see a rheumatologist for fibromyalgia or a neurologist for neuropathic pain. Interdisciplinary pain rehabilitation programs combine these clinicians in one coordinated program, which suits the way CPS affects body, mood and daily life.

Is chronic pain syndrome the same as fibromyalgia?

No, but they overlap heavily. Fibromyalgia is a specific condition defined by widespread pain, fatigue, poor sleep and cognitive symptoms, and it is one of the clearest examples of central sensitization. Chronic pain syndrome is a broader label that can follow any long-lasting pain, such as a back injury, surgery or arthritis, once mood, sleep and function become part of a self-reinforcing cycle.

Related Reading

• Chronic Pain Treatment: A Complete Guide to Evidence-Based Options
• Neuropathic Pain Treatment: From Medications to Regenerative Approaches
• Pain Management Without Opioids: Safer Alternatives That Work
• Fibromyalgia Treatment: Evidence-Based Options
• Ketamine Infusion Therapy for Pain and Depression
• Transcranial Magnetic Stimulation (TMS) Therapy
• Low-Dose Naltrexone: Uses and Evidence

Sources

1. Treede RD, Rief W, Barke A, et al. “Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11).” Pain. 2019;160(1):19-27. doi:10.1097/j.pain.0000000000001384 ↩
2. Woolf CJ. “Central sensitization: Implications for the diagnosis and treatment of pain.” Pain. 2011;152(3 Suppl):S2-15. doi:10.1016/j.pain.2010.09.030 ↩
3. Smallwood RF, Laird AR, Ramage AE, et al. “Structural brain anomalies and chronic pain: a quantitative meta-analysis of gray matter volume.” J Pain. 2013;14(7):663-675. doi:10.1016/j.jpain.2013.03.001 ↩
4. Ji RR, Nackley A, Huh Y, Terrando N, Maixner W. “Neuroinflammation and Central Sensitization in Chronic and Widespread Pain.” Anesthesiology. 2018;129(2):343-366. doi:10.1097/ALN.0000000000002130 ↩
5. Finan PH, Smith MT. “The comorbidity of insomnia, chronic pain, and depression: dopamine as a putative mechanism.” Sleep Med Rev. 2013;17(3):173-183. doi:10.1016/j.smrv.2012.03.003 ↩
6. Diatchenko L, Slade GD, Nackley AG, et al. “Genetic basis for individual variations in pain perception and the development of a chronic pain condition.” Hum Mol Genet. 2005;14(1):135-143. doi:10.1093/hmg/ddi013 ↩
7. Tesarz J, Eich W, Treede RD, Gerhardt A. “Altered pressure pain thresholds and increased wind-up in adult patients with chronic back pain with a history of childhood maltreatment: a quantitative sensory testing study.” Pain. 2016;157(8):1799-1809. doi:10.1097/j.pain.0000000000000586 ↩
8. Mayer TG, Neblett R, Cohen H, et al. “The development and psychometric validation of the central sensitization inventory.” Pain Pract. 2012;12(4):276-285. doi:10.1111/j.1533-2500.2011.00493.x ↩
9. Younger J, Noor N, McCue R, Mackey S. “Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels.” Arthritis Rheum. 2013;65(2):529-538. doi:10.1002/art.37734 ↩
10. Orhurhu V, Orhurhu MS, Bhatia A, Cohen SP. “Ketamine Infusions for Chronic Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials.” Anesth Analg. 2019;129(1):241-254. doi:10.1213/ANE.0000000000004185 ↩
11. Lefaucheur JP, Aleman A, Baeken C, et al. “Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018).” Clin Neurophysiol. 2020;131(2):474-528. doi:10.1016/j.clinph.2019.11.002 ↩
12. Jensen MP, Sherlin LH, Hakiman S, Fregni F. “Neuromodulatory approaches for chronic pain management: research findings and clinical implications.” J Neurother. 2009;13(4):196-213. doi:10.1080/10874200903334371 ↩
13. Louw A, Zimney K, Puentedura EJ, Diener I. “The efficacy of pain neuroscience education on musculoskeletal pain: A systematic review of the literature.” Physiother Theory Pract. 2016;32(5):332-355. doi:10.1080/09593985.2016.1194646 ↩